Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026260 | 0.92 | MAPT (0.48) | MAPTHSD17B10HDAC1KDM4ENR1I2 | |
| SCHEMBL21025781 | 0.89 | HTR6 (0.42) | MAPTHDAC1KDM4EEGFRTDP1 | |
| SCHEMBL15828632 | 0.84 | NPC1 (0.49) | MAPTHSD17B10HDAC1KDM4ENR1I2 | |
| SCHEMBL23479575 | 0.82 | TDP1 (0.49) | MAPTHSD17B10NR1I2TDP1LMNA | |
| SCHEMBL15828631 | 0.82 | MAPT (0.49) | MAPTHSD17B10HDAC1KDM4ENR1I2 | |
| SCHEMBL18731436 | 0.81 | MAPT (0.46) | MAPTHSD17B10HDAC1KDM4EEGFR | |
| SCHEMBL21025786 | 0.81 | TGFBR1 (0.43) | MAPTHSD17B10KDM4EEGFRTDP1 | |
| SCHEMBL12873184 | 0.80 | NPC1 (0.49) | MAPTHSD17B10HDAC1KDM4ENR1I2 | |
| SCHEMBL17678214 | 0.79 | EGFR (0.56) | MAPTHSD17B10HDAC1EGFRTDP1 | |
| SCHEMBL25899200 | 0.79 | NR1I2 (0.43) | MAPTHSD17B10KDM4ENR1I2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20200055823-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20160340314-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9440951-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150239865-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9067887-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20150005287-A2 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20140179675-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239865-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAPT 4550/4885HSD17B10 640/4885HDAC1 746/4885 |
| US-20170362180-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAPT 4550/4885HSD17B10 640/4885HDAC1 746/4885 |
| US-20200055823-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAPT 4550/4885HSD17B10 640/4885HDAC1 746/4885 |
| US-20160340314-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAPT 4550/4885HSD17B10 640/4885HDAC1 746/4885 |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | MAPT 3263/4885HSD17B10 85/4885HDAC1 217/4885 |
| US-20150005287-A2 | QUINOLONE COMPOUND | HAX1, NQO2, VIP | MAPT 4586/4885HSD17B10 624/4885HDAC1 968/4885 |
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAPT 4588/4885HSD17B10 617/4885HDAC1 786/4885 |
| US-20140179675-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | MAPT 4550/4885HSD17B10 640/4885HDAC1 746/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | MAPT 4051/4885HSD17B10 626/4885HDAC1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.